




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 491/22, A61K 31/435 // (C07D 491/22, 311:00, 221:00, 221:00, 209:00) (C07D 491/22, 317:00, 311:00, 221:00, 221:00, 209:00)	A1	(11) International Publication Number: WO 96/37496 (43) International Publication Date: 28 November 1996 (28.11.96)
(21) International Application Number: PCT/EP96/02008 (22) International Filing Date: 10 May 1996 (10.05.96) (30) Priority Data: 9510716.5 26 May 1995 (26.05.95) GB (71) Applicant (for all designated States except US): PHARMACIA S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): CABRI, Walter [IT/IT]; Via Massimo d'Azeglio, 29, I-20089 Rozzano (IT). CANDI-ANI, Ilaria [IT/IT]; Via del Chisso, 5, I-21052 Busto Arsizio (IT). BEDESCHI, Angelo [IT/IT]; Via Pietro Redaelli, 11, I-20146 Milano (IT). ZARINI, Franco [IT/IT]; Via Giuseppe di Vittorio, 41, I-20019 Settimo Milanese (IT). PENCO, Sergio [IT/IT]; Via Milly Mignone, 5, I-20153 Milano (IT).		(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, UA, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION		
(57) Abstract <p>The present invention relates to substituted camptothecin derivatives of formula (I) wherein the symbol --- represents a single or double bond; R_1, R_2 and R_3 are as defined under (a) or (b) below: (a) R_1 and R_2 are, each independently, hydrogen; C_1-C_4 alkyl; C_3-C_7 cycloalkyl; phenyl C_1-C_6 alkyl; an optionally substituted phenyl ring; $\text{-NR}_5\text{R}_6$ wherein one of R_5 and R_6 is hydrogen, C_1-C_6 alkyl or benzyl and the other is hydrogen, C_1-C_6 alkanoyl, an optionally substituted C_1-C_6 alkoxy carbonyl, an optionally substituted benzoyl, phenyl C_1-C_6 alkanoyl, an optionally substituted C_1-C_6 alkoxy carbonyl, an optionally substituted phenoxy carbonyl or phenyl C_1-C_6 alkoxy carbonyl, or R_5 and R_6, combined together with the nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring residue; COOR_8 wherein R_8 is hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl or phenyl C_1-C_6 alkyl; or COR_9 wherein R_9 is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl C_1-C_6 alkyl, an optionally substituted phenyl ring or $\text{NR}_{10}\text{R}_{11}$ wherein R_{10} and R_{11} are, each independently, hydrogen or C_1-C_6 alkyl; and R_3 is hydrogen, C_1-C_6 alkyl or an optionally substituted phenyl ring; or (b) R_1 and R_3, combined together, form a 5-8 membered, optionally substituted, carbomonocyclic ring; and R_2 is hydrogen, C_1-C_4 alkyl or C_3-C_7 cycloalkyl; R_4 is hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl or phenyl C_1-C_6 alkyl; X is hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkoxy, C_1-C_6 alkanoyloxy, benzoyloxy, amino, hydroxy, nitro, halogen or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof. The compounds according to the invention are useful in therapy as antitumor agents.</p> <div style="text-align: right;">  <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION

The present invention relates to new substituted camptothecin
5 derivatives possessing antitumor activity, to a process for
their preparation, and to pharmaceutical compositions
containing them.

Background of the invention

10 Camptothecin and some of its analogs display potent antitumor
activity by the inhibition of Topoisomerase I, that is an
enzyme involved in some important cellular functions and
cellular growth (see, for instance, Wani et al., J. Med. Chem.
1987, 30, 1774; Hsiang et al., Cancer Res. 1989, 49, 4385;
15 Cancer Res. 1989, 49, 1465).

Anticancer activity of Camptothecin both in vitro and in vivo
is significantly greater for the lactone versus the
carboxylate form (as disclosed, for instance, by W.J.
Slichenmyer et al., in "The Current Status of Camptothecin
20 Analogues as Antitumor Agents", J. Natl. Cancer Inst. 1993,
85, 271-291, and reference therein), since a closed α -hydroxy
lactone ring is an important structural requirement for both
passive diffusion of drug into cancer cells, as well as for
successful drug interaction with the pharmacological target.


25 It has recently been pointed out that, in the presence of
biologically relevant levels of human albumin, the
biologically active form of camptothecin has a very short
half-life (about 12 min.), and 2 hours after drug addition to
human plasma, a percentage greater than 99% of the drug has
30 converted to camptothecin carboxylate, the biologically
inactive and potentially toxic form of the drug (see Burke,
G.T.; Mi, Z. "The Structural Basis of Camptothecin

Interactions with Human Serum Albumin: Impact on Drug Stability", J. Med. Chem. 1994, 37, 40-46). The same authors disclose also the importance of the substitution in 9 and 7 positions on the camptothecin nucleus in order to improve drug stability in the presence of albumin.

There is therefore a need to find new camptothecin derivatives that have high intrinsic potency, and may gain, at the same time, stability in the presence of serum albumin.

10 Description of the invention

Accordingly, the present invention relates to substituted camptothecin derivatives of formula (I)



wherein

15 the symbol ---- represents a single or double bond;

R_1 , R_2 and R_3 are as defined under (a) or (b) below:

(a) R_1 and R_2 are, each independently,
hydrogen;

C_1 - C_4 alkyl;

20 C_3 - C_7 cycloalkyl;

phenyl C_1 - C_6 alkyl;


an optionally substituted phenyl ring;

$-NR_5R_6$ wherein one of R_5 and R_6 is hydrogen, C_1 - C_6 alkyl or benzyl and the other is hydrogen C_1 - C_6 alkanoyl, an

25 optionally substituted C_1 - C_6 alkoxycarbonyl, an optionally substituted benzoyl, phenyl C_1 - C_6 alkanoyl, an optionally substituted phenoxycarbonyl or phenyl C_1 - C_6

-3-

alkoxycarbonyl, or R_5 and R_6 , combined together with the nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring residue, represented by a group



wherein W is $-C=O$, R_7 is hydrogen or C_1-C_6 alkyl and n is an integer of 2 to 5;

$COOR_8$ wherein R_8 is hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl or phenyl C_1-C_6 alkyl; or

COR_9 wherein R_9 is C_1-C_6 alkyl, C_3-C_7 cycloalkyl, phenyl C_1-C_6 alkyl, an optionally

substituted phenyl ring or $NR_{10}R_{11}$ wherein R_{10} and R_{11} are, each independently, hydrogen or C_1-C_6 alkyl; and

R_3 is hydrogen, C_1-C_6 alkyl or an optionally substituted phenyl ring; or

(b) R_1 and R_3 , combined together, form a 5-8 membered, optionally substituted, carbomonocyclic ring; and

R_2 is hydrogen, C_1-C_4 alkyl or C_3-C_7 cycloalkyl;

R_4 is hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl or phenyl C_1-C_6 alkyl;

X is hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, C_3-C_7 cycloalkoxy, C_1-C_6 alkanoyloxy, benzoyloxy, amino, hydroxy, nitro, halogen or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof.

In the formulae of the present specification, a dotted line (---) indicates a substituent below the plane of the ring; a wedged line (\blacktriangleleft) indicates a substituent above the plane of the ring.


When in a compound of formula (I) the symbol ---- means a double bond, both Z and E isomers and a mixture of Z and E isomers are included into the scope of the present invention.

Pharmaceutically acceptable salts according the invention are
5 the salts with pharmaceutically acceptable acids, both inorganic acids such as, e.g. hydrochloric, sulfuric, phosphoric, diphosphoric, hydrobromic or nitric acid, and organic acids such as, e.g., citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic,
10 methanesulfonic, ethanesulfonic, benzenesulfonic, or p-toluensulfonic acid.

Pharmaceutically acceptable salts of the compounds of formula (I) containing an acidic, i.e. carboxy, group with pharmaceutically acceptable bases are also included in the
15 scope of the present invention.

Pharmaceutically acceptable bases may be both inorganic bases such as, for instance, alkali metal, e.g. sodium or potassium, or alkaline earth metal, e.g. calcium or magnesium, hydroxides, and organic bases such as, for instance, alkyl
20 amines, e.g. methylamine or triethylamine, aralkylamines, e.g. benzylamine, dibenzylamine, a- or b-phenyl-ethylamine, or heterocyclic amines such as, e.g., piperidine, 1-methyl-piperidine, piperazine or morpholine.

An optionally substituted phenyl ring may be represented by a
25 group




wherein

Q, linked to the ortho, meta or para position of the phenyl ring, represents hydrogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆
30 alkanoyloxy, nitro or halogen.

Preferably Q is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy or halogen.

Particularly preferred values of Q are hydrogen, methoxy and chlorine.


An optionally substituted benzoyl may be represented by a group



5

wherein Q is as defined above.

An optionally substituted phenoxycarbonyl may be represented by a group



10 wherein Q is as defined above.

A 5-8 membered, optionally substituted carbomonocyclic ring is, when the symbol ---- is used to denote a single bond, for example cyclopentyl or cyclohexyl, or, when the symbol ==== is used to denote a double bond, cyclopenten-1-yl or cyclohexen-1-yl.

15

In the present specification, the hydrocarbon chain of the alkyl, alkoxy, alkanoyl, alkanoyloxy and alkoxycarbonyl groups may be a straight or branched chain.

Preferably, C₁-C₆ alkyl is C₁-C₄ alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or t-butyl.

20

Preferably, C₁-C₄ alkyl is methyl, ethyl or propyl.

Preferably, C₃-C₇ cycloalkyl is C₄-C₆ cycloalkyl, e.g. cyclobutyl, cyclopentyl or cyclohexyl.

Preferably, C₁-C₆ alkoxy is C₁-C₄ alkoxy, e.g. methoxy, ethoxy or propoxy.

25


Preferably, C₁-C₆ alkanoyl is C₁-C₄ alkanoyl, e.g. methanoyl, ethanoyl or propanoyl.

Preferably, C₁-C₆ alkanoyloxy is C₁-C₄ alkanoyloxy, e.g. methanoyloxy, ethanoyloxy or propanoyloxy.

Preferably, C_1 - C_6 alkoxy carbonyl is C_1 - C_4 alkoxy carbonyl, e.g. methoxy carbonyl, ethoxy carbonyl, n-propoxy carbonyl or isopropoxy carbonyl.

Preferably, an optionally substituted C_1 - C_6 alkoxy carbonyl is
5 trichloroethoxy carbonyl.

Preferred meanings of the heteromonocyclic ring residue represented by the above defined group (G) are



A preferred class of compounds according to this invention is
10 represented by compounds of the above formula (I) wherein the symbol ---- represents a single or double bond; R_1 and R_2 are, each independently, hydrogen;

- NR_5R_6 wherein one of R_5 and R_6 is hydrogen and the other is hydrogen, C_1 - C_6 alkanoyl, an optionally substituted benzoyl,
15 phenyl C_1 - C_6 alkanoyl, C_1 - C_6 alkoxy carbonyl, phenoxy-carbonyl or phenyl C_1 - C_6 alkoxy carbonyl;

$COOR_8$ wherein R_8 is hydrogen or C_1 - C_6 alkyl; or

COR_9 wherein R_9 is C_1 - C_6 alkyl, unsubstituted phenyl or $NR_{10}R_{11}$ wherein R_{10} and R_{11} are both hydrogen;

20 R_3 is hydrogen;

R_4 is hydrogen or C_1 - C_6 alkyl;

X is hydrogen, hydroxy, amino, C_1 - C_6 alkoxy or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof.

25 Examples of specific compounds preferred under the invention are the following:

9-vinyl camptothecin (1);

(E)-9-(2-methoxycarbonyl-ethenyl)camptothecin (2);

9-(2-hydroxycarbonyl-ethenyl)camptothecin (3);

30 (Z)-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (4);

- 9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (5);
9-(3-oxo-but-1-enyl)camptothecin (6);
9-(3-oxo-3-phenyl-propenyl)camptothecin (7);
9-(2-aminocarbonyl-ethenyl)camptothecin (8);
5 7-ethyl-9-vinyl camptothecin (9);
7-ethyl-9-(2-methoxycarbonyl-ethenyl)camptothecin (10);
7-ethyl-9-(2-hydroxycarbonyl-ethenyl)camptothecin (11);
7-ethyl-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (12);
10 7-ethyl-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (13);
7-ethyl-9-(3-oxo-but-1-enyl)camptothecin (14);
7-ethyl-9-(3-oxo-3-phenyl-propenyl)camptothecin (15);
7-ethyl-9-(2-aminocarbonyl-ethenyl)camptothecin (16);
15 10-vinyl camptothecin (17);
(E)-10-(2-methoxycarbonyl-ethenyl)camptothecin (18);
10-(2-hydroxycarbonyl-ethenyl)camptothecin (19);
10-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (20);
10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (21);
20 10-(3-oxo-but-1-enyl)camptothecin (22);
10-(3-oxo-3-phenyl-propenyl)camptothecin (23);
10-(2-aminocarbonyl-ethenyl)camptothecin (24);
7-ethyl-10-vinyl camptothecin (25);
7-ethyl-10-(2-methoxycarbonyl-ethenyl)camptothecin (26);
25 7-ethyl-10-(2-hydroxycarbonyl-ethenyl)camptothecin (27);
7-ethyl-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (28);
7-ethyl-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (29);
30 7-ethyl-10-(3-oxo-but-1-enyl)camptothecin (30);
7-ethyl-10-(3-oxo-3-phenyl-propenyl)camptothecin (31);
7-ethyl-10-(2-aminocarbonyl-ethenyl)camptothecin (32);

- 10-hydroxy-9-vinyl camptothecin (33);
10-hydroxy-9-(2-methoxycarbonyl-ethenyl)camptothecin (34);
10-hydroxy-9-(2-hydroxycarbonyl-ethenyl)camptothecin (35);
10-hydroxy-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)
5 camptothecin (36);
10-hydroxy-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (37);
10-hydroxy-9-(3-oxo-but-1-enyl)camptothecin (38);
10-hydroxy-9-(3-oxo-3-phenyl-propenyl)camptothecin (39);
10 10-hydroxy-9-(2-aminocarbonyl-ethenyl)camptothecin (40);
10,11-methylenedioxy-9-vinyl camptothecin (41);
10,11-methylenedioxy-9-(2-methoxycarbonyl-ethenyl)camptothecin
(42);
10,11-methylenedioxy-9-(2-hydroxycarbonyl-ethenyl)camptothecin
15 (43);
10,11-methylenedioxy-9-(2-acetylamino-2-methoxycarbonyl-
ethenyl) camptothecin (44);
10,11-methylenedioxy-9-(2-acetylamino-2-hydroxycarbonyl-
ethenyl) camptothecin (45);
20 10,11-methylenedioxy-9-(3-oxo-but-1-enyl)camptothecin (46);
10,11-methylenedioxy-9-(3-oxo-3-phenyl-propenyl)camptothecin
(47);
10,11-methylenedioxy-9-(2-aminocarbonyl-ethenyl)camptothecin
(48);
25 10-methoxy-9-vinyl camptothecin (49);
10-methoxy-9-(2-methoxycarbonyl-ethenyl)camptothecin (50);
10-methoxy-9-(2-hydroxycarbonyl-ethenyl)camptothecin (51);
10-methoxy-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (52);
30 10-methoxy-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (53);
10-methoxy-9-(3-oxo-but-1-enyl)camptothecin (54);

- 10-methoxy-9-(3-oxo-3-phenyl-propenyl)camptothecin (55);
10-methoxy-9-(2-aminocarbonyl-ethenyl)camptothecin (56);
11-vinyl camptothecin (57);
11-(2-methoxycarbonyl-ethenyl)camptothecin (58);
5 11-(2-hydroxycarbonyl-ethenyl)camptothecin (59);
11-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (60);
11-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (61);
11-(3-oxo-but-1-enyl)camptothecin (62);
11-(3-oxo-3-phenyl-propenyl)camptothecin (63);
10 11-(2-aminocarbonyl-ethenyl)camptothecin (64);
12-vinyl camptothecin (65);
(E)-12-(2-methoxycarbonyl-ethenyl)camptothecin (66);
12-(2-hydroxycarbonyl-ethenyl)camptothecin (67);
(Z)-12-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin
15 (68);
12-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (69);
12-(3-oxo-but-1-enyl)camptothecin (70);
12-(3-oxo-3-phenyl-propenyl)camptothecin (71);
12-(2-aminocarbonyl-ethenyl)camptothecin (72);
20 9-amino-10-vinyl camptothecin (73);
9-amino-10-(2-methoxycarbonyl-ethenyl)camptothecin (74);
9-amino-10-(2-hydroxycarbonyl-ethenyl)camptothecin (75);
9-amino-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (76);
25 9-amino-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (77);
9-amino-10-(3-oxo-but-1-enyl)camptothecin (78);
9-amino-10-(3-oxo-3-phenyl-propenyl)camptothecin (79);
9-amino-10-(2-aminocarbonyl-ethenyl)camptothecin (80);
30 7-ethyl-9-amino-10-vinyl camptothecin (81);
7-ethyl-9-amino-10-(2-methoxycarbonyl-ethenyl)camptothecin
(82);

- 7-ethyl-9-amino-10-(2-hydroxycarbonyl-ethenyl)camptothecin (83);
- 7-ethyl-9-amino-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (84);
- 5 7-ethyl-9-amino-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (85);
- 7-ethyl-9-amino-10-(3-oxo-but-1-enyl)camptothecin (86);
- 7-ethyl-9-amino-10-(3-oxo-3-phenyl-propenyl)camptothecin (87);
- 7-ethyl-9-amino-10-(2-aminocarbonyl-ethenyl)camptothecin (88);
- 10 9-ethyl camptothecin (1');
- 9-(2-methoxycarbonyl-ethyl)camptothecin (2');
- 9-(2-hydroxycarbonyl-ethyl)camptothecin (3');
- 9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin (4');
- 9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (5');
- 15 9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (6');
- 9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (7');
- 9-(3-oxo-butyl)camptothecin (8');
- 9-(3-oxo-3-phenyl-propyl)camptothecin (9');
- 9-(2-aminocarbonyl-ethyl)camptothecin (10');
- 20 7-ethyl-9-ethyl camptothecin (11');
- 7-ethyl-9-(2-methoxycarbonyl-ethyl)camptothecin (12');
- 7-ethyl-9-(2-hydroxycarbonyl-ethyl)camptothecin (13');
- 7-ethyl-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin (14');
- 25 7-ethyl-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (15');
- 7-ethyl-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (16');
- 7-ethyl-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (17');
- 30 7-ethyl-9-(3-oxo-butyl)camptothecin (18');
- 7-ethyl-9-(3-oxo-3-phenyl-propyl)camptothecin (19');

- 7-ethyl-9-(2-aminocarbonyl-ethyl)camptothecin (20');
10-ethyl camptothecin (21');
10-(2-methoxycarbonyl-ethyl)camptothecin (22');
10-(2-hydroxycarbonyl-ethyl)camptothecin (23');
5 10-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin
(24');
10-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (25');
10-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (26');
10-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (27');
10 10-(3-oxo-butyl)camptothecin (28');
10-(3-oxo-3-phenyl-propyl)camptothecin (29');
10-(2-aminocarbonyl-ethyl)camptothecin (30');
7-ethyl-10-ethyl camptothecin (31');
7-ethyl-10-(2-methoxycarbonyl-ethyl)camptothecin (32');
15 7-ethyl-10-(2-hydroxycarbonyl-ethyl)camptothecin (33');
7-ethyl-10-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (34');
7-ethyl-10-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
(35');
20 7-ethyl-10-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
(36');
7-ethyl-10-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (37');
7-ethyl-10-(3-oxo-butyl)camptothecin (38');
25 7-ethyl-10-(3-oxo-3-phenyl-propyl)camptothecin (39');
7-ethyl-10-(2-aminocarbonyl-ethyl)camptothecin (40');
11-ethyl camptothecin (41');
11-(2-methoxycarbonyl-ethyl)camptothecin (42');
11-(2-hydroxycarbonyl-ethyl)camptothecin (43');
30 11-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin
(44');
11-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (45');

- 11-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (46');
11-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin
(47');
11-(3-oxo-butyl)camptothecin (48');
5 11-(3-oxo-3-phenyl-propyl)camptothecin (49');
11-(2-aminocarbonyl-ethyl)camptothecin (50');
9-amino-12-ethyl camptothecin (51');
9-amino-12-(2-methoxycarbonyl-ethyl)camptothecin (52');
9-amino-12-(2-hydroxycarbonyl-ethyl)camptothecin (53');
10 9-amino-12-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (54');
9-amino-12-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
(55');
9-amino-12-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
15 56');
9-amino-12-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (57');
9-amino-12-(3-oxo-butyl)camptothecin (58');
9-amino-12-(3-oxo-3-phenyl-propyl)camptothecin (59');
20 9-amino-12-(2-aminocarbonyl-ethyl)camptothecin (60');
10-amino-9-ethyl camptothecin (61');
10-amino-9-(2-methoxycarbonyl-ethyl)camptothecin (62');
10-amino-9-(2-hydroxycarbonyl-ethyl)camptothecin (63');
10-amino-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
25 camptothecin (64');
10-amino-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
(65');
10-amino-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
(66');
30 10-amino-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (67');
10-amino-9-(3-oxo-butyl)camptothecin (68');

- 10-amino-9-(3-oxo-3-phenyl-3-one-propyl)camptothecin (69');
10-amino-9-(2-aminocarbonyl-ethyl)camptothecin (70');
12-ethyl camptothecin (71');
12-(2-methoxycarbonyl-ethyl)camptothecin (72');
5 12-(2-hydroxycarbonyl-ethyl)camptothecin (73');
12-[(2R,S)-(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin (74');
12-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (75');
12-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (76');
10 12-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (77');
12-(3-oxo-butyl)camptothecin (78');
12-(3-oxo-3-phenyl-propyl)camptothecin (79');
12-(2-aminocarbonyl-ethyl)camptothecin (80');
10-hydroxy-9-ethyl camptothecin (81');
15 10-hydroxy-9-(2-methoxycarbonyl-ethyl)camptothecin (82');
10-hydroxy-9-(2-hydroxycarbonyl-ethyl)camptothecin (83');
10-hydroxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (84');
10-hydroxy-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
20 (85');
10-hydroxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
(86');
10-hydroxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (87');
25 10-hydroxy-9-(3-oxo-butyl)camptothecin (88');
10-hydroxy-9-(3-oxo-3-phenyl-3-one-propyl)camptothecin (89');
10-hydroxy-9-(2-aminocarbonyl-ethyl)camptothecin (90');
10,11-methylenedioxy-9-ethyl camptothecin (91');
10,11-methylenedioxy-9-(2-methoxycarbonyl-ethyl)camptothecin
30 (92');
10,11-methylenedioxy-9-(2-hydroxycarbonyl-ethyl)camptothecin
(93');

- 10,11-methylenedioxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin (94');
10,11-methylenedioxy-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (95');
5 10,11-methylenedioxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (96');
10,11-methylenedioxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (97');
10,11-methylenedioxy-9-(3-oxo-butyl)camptothecin (98');
10 10,11-methylenedioxy-9-(3-oxo-3-phenyl-propyl)camptothecin (99');
10,11-methylenedioxy-9-(2-aminocarbonyl-ethyl)camptothecin (100');
10-methoxy-9-ethyl camptothecin (101');
15 10-methoxy-9-(2-methoxycarbonyl-ethyl)camptothecin (102');
10-methoxy-9-(2-hydroxycarbonyl-ethyl)camptothecin (103');
10-methoxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin (104');
10-methoxy-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
20 (105');
10-methoxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (106');
10-methoxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (107');
25 10-methoxy-9-(3-oxo-butyl)camptothecin (108');
10-methoxy-9-(3-oxo-3-phenyl-propyl)camptothecin (109');
10-methoxy-9-(2-aminocarbonyl-ethyl)camptothecin (110');
and, where a salifiable substituent is present on the molecule framework, their pharmaceutically acceptable salts.
- 30 The structural formula of the above listed compounds is illustrated in the following Table 1 with reference to the above formula (I) wherein the symbol ---- represents a double

bond, and Table 2 with reference to the above formula (I) wherein the symbol ---- represents a single bond.




Table 1

Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
1	-CH=CH ₂	-	-	-	-	H	H
2	-CH=CH-COOR ₈	-	-	CH ₃	-	H	H
3	-CH=CH-COOR ₈	-	-	H	-	H	H
4	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
5	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
6	-CH=CH-COR ₉	-	-	-	CH ₃	H	H
7	-CH=CH-COR ₉	-	-	-	Ph	H	H
8	-CH=CH-COR ₉	-	-	-	NH ₂	H	H
9	-CH=CH ₂	-	-	-	-	Et	H
10	-CH=CH-COOR ₈	-	-	CH ₃	-	Et	H
11	-CH=CH-COOR ₈	-	-	H	-	Et	H
12	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	Et	H
13	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	Et	H
14	-CH=CH-COR ₉	-	-	-	CH ₃	Et	H
15	-CH=CH-COR ₉	-	-	-	Ph	Et	H
16	-CH=CH-COR ₉	-	-	-	NH ₂	Et	H
Compound	10-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
17	-CH=CH ₂	-	-	-	-	H	H
18	-CH=CH-COOR ₈	-	-	CH ₃	-	H	H
19	-CH=CH-COOR ₈	-	-	H	-	H	H
20	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
21	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
22	-CH=CH-COR ₉	-	-	-	CH ₃	H	H
23	-CH=CH-COR ₉	-	-	-	Ph	H	H
24	-CH=CH-COR ₉	-	-	-	NH ₂	H	H

Table 1 (continued)

Compound	10-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
25	-CH=CH ₂	-	-	-	-	Et	H
26	-CH=CH-COOR ₈	-	-	CH ₃	-	Et	H
27	-CH=CH-COOR ₈	-	-	H	-	Et	H
28	-CH=C-COOR ₈ NR ₃ R ₆	H	COCH ₃	CH ₃	-	Et	H
29	-CH=C-COOR ₈ NR ₃ R ₆	H	COCH ₃	H	-	Et	H
30	-CH=CH-COR ₉	-	-	-	CH ₃	Et	H
31	-CH=CH-COR ₉	-	-	-	Ph	Et	H
32	-CH=CH-COR ₉	-	-	-	NH ₂	Et	H
Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
33	-CH=CH ₂	-	-	-	-	H	10-OH
34	-CH=CH-COOR ₈	-	-	CH ₃	-	H	10-OH
35	-CH=CH-COOR ₈	-	-	H	-	H	10-OH
36	-CH=C-COOR ₈ NR ₃ R ₆	H	COCH ₃	CH ₃	-	H	10-OH
37	-CH=C-COOR ₈ NR ₃ R ₆	H	COCH ₃	H	-	H	10-OH
38	-CH=CH-COR ₉	-	-	-	CH ₃	H	10-OH
39	-CH=CH-COR ₉	-	-	-	Ph	H	10-OH
40	-CH=CH-COR ₉	-	-	-	NH ₂	H	10-OH
41	-CH=CH ₂	-	-	-	-	H	10,11-OCH ₂ O-
42	-CH=CH-COOR ₈	-	-	CH ₃	-	H	10,11-OCH ₂ O-
43	-CH=CH-COOR ₈	-	-	H	-	H	10,11-OCH ₂ O-
44	-CH=C-COOR ₈ NR ₃ R ₆	H	COCH ₃	CH ₃	-	H	10,11-OCH ₂ O-
45	-CH=C-COOR ₈ NR ₃ R ₆	H	COCH ₃	H	-	H	10,11-OCH ₂ O-
46	-CH=CH-COR ₉	-	-	-	CH ₃	H	10,11-OCH ₂ O-
47	-CH=CH-COR ₉	-	-	-	Ph	H	10,11-OCH ₂ O-
48	-CH=CH-COR ₉	-	-	-	NH ₂	H	10,11-OCH ₂ O-

Table 1 (continued)

Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
49	-CH=CH ₂	-	-	-	-	H	10-OCH ₃
50	-CH=CH-COOR ₈	-	-	CH ₃	-	H	10-OCH ₃
51	-CH=CH-COOR ₈	-	-	H	-	H	10-OCH ₃
52	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	10-OCH ₃
53	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	10-OCH ₃
54	-CH=CH-COR ₉	-	-	-	CH ₃	H	10-OCH ₃
55	-CH=CH-COR ₉	-	-	-	Ph	H	10-OCH ₃
56	-CH=CH-COR ₉	-	-	-	NH ₂	H	10-OCH ₃
Compound	11-substituted	R ₅	R ₆	R ₈	R ₉	R ₄	X
57	-CH=CH ₂	-	-	-	-	H	H
58	-CH=CH-COOR ₈	-	-	CH ₃	-	H	H
59	-CH=CH-COOR ₈	-	-	H	-	H	H
60	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
61	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
62	-CH=CH-COR ₉	-	-	-	CH ₃	H	H
63	-CH=CH-COR ₉	-	-	-	Ph	H	H
64	-CH=CH-COR ₉	-	-	-	NH ₂	H	H

Table 1 (continued)

Compound	12-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
65	-CH=CH ₂	-	-	-	-	H	H
66	-CH=CH-COOR ₈	-	-	CH ₃	-	H	H
67	-CH=CH-COOR ₈	-	-	H	-	H	H
68	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
69	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
70	-CH=CH-COR ₉	-	-	-	CH ₃	H	H
71	-CH=CH-COR ₉	-	-	-	Ph	H	H
72	-CH=CH-COR ₉	-	-	-	NH ₂	H	H
Compound	10-substituent	R ₅	R ₆	R ₈	R ₉	R	X
73	-CH=CH ₂	-	-	-	-	H	9-NH ₂
74	-CH=CH-COOR ₈	-	-	CH ₃	-	H	9-NH ₂
75	-CH=CH-COOR ₈	-	-	H	-	H	9-NH ₂
76	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	9-NH ₂
77	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	9-NH ₂
78	-CH=CH-COR ₉	-	-	-	CH ₃	H	9-NH ₂
79	-CH=CH-COR ₉	-	-	-	Ph	H	9-NH ₂
80	-CH=CH-COR ₉	-	-	-	NH ₂	H	9-NH ₂
81	-CH=CH ₂	-	-	-	-	Et	9-NH ₂
82	-CH=CH-COOR ₈	-	-	CH ₃	-	Et	9-NH ₂
83	-CH=CH-COOR ₈	-	-	H	-	Et	9-NH ₂
84	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	Et	9-NH ₂
85	-CH=C-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	Et	9-NH ₂
86	-CH=CH-COR ₉	-	-	-	CH ₃	Et	9-NH ₂
87	-CH=CH-COR ₉	-	-	-	Ph	Et	9-NH ₂
88	-CH=CH-COR ₉	-	-	-	NH ₂	Et	9-NH ₂

Table 2

Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
1'	-CH ₂ -CH ₃	-	-	-	-	H	H
2'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	H
3'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	H
4'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
5'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	H
6'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	H
7'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
8'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	H
9'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	H
10'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	H
11'	-CH ₂ -CH ₃	-	-	-	-	Et	H
12'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	Et	H
13'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	Et	H
14'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	Et	H
15'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	Et	H
16'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	Et	H
17'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	Et	H
18'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	Et	H
19'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	Et	H
20'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	Et	H

Table 2 (continued)

Compound	10-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
21'	-CH ₂ -CH ₃	-	-	-	-	H	H
22'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	H
23'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	H
24'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
25'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	H
26'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	H
27'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
28'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	H
29'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	H
30'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	H
31'	-CH ₂ -CH ₃	-	-	-	-	Et	H
32'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	Et	H
33'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	Et	H
34'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	Et	H
35'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	Et	H
36'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	Et	H
37'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	Et	H
38'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	Et	H
39'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	Et	H
40'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	Et	H

Table 2 (continued)

Compound	11-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
41'	-CH ₂ -CH ₃	-	-	-	-	H	H
42'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	H
43'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	H
44'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
45'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	H
46'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	H
47'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
48'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	H
49'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	H
50'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	H
Compound	12-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
51'	-CH ₂ -CH ₃	-	-	-	-	H	9-NH ₂
52'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	9-NH ₂
53'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	9-NH ₂
54'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	9-NH ₂
55'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	9-NH ₂
56'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	9-NH ₂
57'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	9-NH ₂
58'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	9-NH ₂
59'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	9-NH ₂
60'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	9-NH ₂

Table 2 (continued)

Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
61'	-CH ₂ -CH ₃	-	-	-	-	H	10-NH ₂
62'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	10-NH ₂
63'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	10-NH ₂
64'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	10-NH ₂
65'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	10-NH ₂
66'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	10-NH ₂
67'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	10-NH ₂
68'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	10-NH ₂
69'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	10-NH ₂
70'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	10-NH ₂
Compound	12-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
71'	-CH ₂ -CH ₃	-	-	-	-	H	H
72'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	H
73'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	H
74'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	H
75'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	H
76'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	H
77'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	H
78'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	H
79'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	H
80'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	H

Table 2 (continued)

Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
81'	-CH ₂ -CH ₃	-	-	-	-	H	10-OH
82'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	10-OH
83'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	10-OH
84'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	10-OH
85'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	10-OH
86'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	10-OH
87'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	10-OH
88'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	10-OH
89'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	10-OH
90'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	10-OH
91'	-CH ₂ -CH ₃	-	-	-	-	H	10,11-OCH ₂ O-
92'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	10,11-OCH ₂ O-
93'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	10,11-OCH ₂ O-
94'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	CH ₃	-	H	10,11-OCH ₂ O-
95'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	CH ₃	-	H	10,11-OCH ₂ O-
96'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	H	H	-	H	10,11-OCH ₂ O-
97'	-CH ₂ -CH-COOR ₈ NR ₅ R ₆	H	COCH ₃	H	-	H	10,11-OCH ₂ O-
98'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	10,11-OCH ₂ O-
99'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	10,11-OCH ₂ O-
100'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	10,11-OCH ₂ O-


Table 2 (continued)

Compound	9-substituent	R ₅	R ₆	R ₈	R ₉	R ₄	X
101'	-CH ₂ -CH ₃	-	-	-	-	H	10-OCH ₃
102'	-(CH ₂) ₂ -COOR ₈	-	-	CH ₃	-	H	10-OCH ₃
103'	-(CH ₂) ₂ -COOR ₈	-	-	H	-	H	10-OCH ₃
104'	$\begin{array}{c} \text{-CH}_2\text{-CH-COOR}_8 \\ \\ \text{NR}_5\text{R}_6 \end{array}$	H	COCH ₃	CH ₃	-	H	10-OCH ₃
105'	$\begin{array}{c} \text{-CH}_2\text{-CH-COOR}_8 \\ \\ \text{NR}_5\text{R}_6 \end{array}$	H	H	CH ₃	-	H	10-OCH ₃
106'	$\begin{array}{c} \text{-CH}_2\text{-CH-COOR}_8 \\ \\ \text{NR}_5\text{R}_6 \end{array}$	H	H	H	-	H	10-OCH ₃
107'	$\begin{array}{c} \text{-CH}_2\text{-CH-COOR}_8 \\ \\ \text{NR}_5\text{R}_6 \end{array}$	H	COCH ₃	H	-	H	10-OCH ₃
108'	-(CH ₂) ₂ -COR ₉	-	-	-	CH ₃	H	10-OCH ₃
109'	-(CH ₂) ₂ -COR ₉	-	-	-	Ph	H	10-OCH ₃
110'	-(CH ₂) ₂ -COR ₉	-	-	-	NH ₂	H	10-OCH ₃

In Tables 1 and 2, the symbols Et and Ph stand respectively
 5 for ethyl and phenyl.

The present invention includes also in its scope a process for
 preparing the compounds of formula (I) as defined above, said
 process comprising

- 10 1) reacting a compound of formula (II)




wherein

R_{11} is a halogen atom, $-\text{OSO}_2R_{12}$ wherein R_{12} is $\text{C}_1\text{-C}_5$ alkyl unsubstituted or substituted at the terminal carbon atom by one, two or three halogen atoms or an optionally substituted phenyl ring;

R_4 is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_7$ cycloalkyl or phenyl $\text{C}_1\text{-C}_6$ alkyl; and

X is hydrogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_7$ cycloalkyl, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_3\text{-C}_7$ cycloalkoxy, $\text{C}_1\text{-C}_6$ alkanoyloxy, benzoyloxy, amino hydroxy, nitro, halogen or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, with a compound of formula (III)




wherein

R_1 , R_2 and R_3 are as defined under (a) or (b) below:

- (a) R_1 and R_2 are each independently hydrogen; $\text{C}_1\text{-C}_4$ alkyl; $\text{C}_3\text{-C}_7$ cycloalkyl; phenyl $\text{C}_1\text{-C}_6$ alkyl; an optionally substituted phenyl ring;
- $-\text{NR}_5\text{R}_6$ wherein one of R_5 and R_6 is hydrogen, $\text{C}_1\text{-C}_6$ alkyl or benzyl and the other is hydrogen, $\text{C}_1\text{-C}_6$ alkanoyl, an optionally substituted benzoyl, phenyl $\text{C}_1\text{-C}_6$ alkanoyl, an optionally substituted $\text{C}_1\text{-C}_6$ alkoxy carbonyl, an optionally substituted phenoxy carbonyl or phenyl $\text{C}_1\text{-C}_6$ alkoxy carbonyl, or R_5 and R_6 , combined together with the

nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring, represented by a group (G)



- 5 wherein W is -C=O, R₇ is hydrogen or C₁-C₆ alkyl and n is an integer of 2 to 5;
 COOR₈ wherein R₈ is C₁-C₆ alkyl, C₃-C₇ cycloalkyl or phenyl C₁-C₆ alkyl; or
 COR₉ wherein R₉ is C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl
 10 C₁-C₆ alkyl, an optionally substituted phenyl ring, NR₁₀R₁₁ wherein R₁₀ and R₁₁ are each independently hydrogen or C₁-C₆ alkyl; and
 R₃ is hydrogen, C₁-C₆ alkyl or an optionally substituted phenyl; or
 15 (b) R₁ and R₃, combined together, form a 5-8 membered, optionally substituted carbomonocyclic ring; and
 R₂ is hydrogen, C₁-C₄ alkyl or C₃-C₇ cycloalkyl;
 so obtaining a compound of formula (I) wherein the symbol ---- represents a double bond;
 20 and, if desired,
 2) reducing a compound of formula (I) as obtained under step 1) into a corresponding compound of formula (I) wherein the symbol ---- represents a single bond, and/or if desired, salifying a compound of formula (I).
 25 The starting compounds of formula (II) have a 20 (S)-configuration which is retained through the process leading to the compounds of formula (I). The compounds of formula (II) are typically free of the corresponding 20 (R)-isomers. However, said process may be applied to a racemic mixture of a
 30 compound of formula (II) and the corresponding 20 (R)-isomer.

In that case, a racemic mixture of a compound of formula (I) and a 20 (R)- isomer of a compound of formula (I) is obtained. When one or more new stereogenic centers are created in one of the above mentioned steps, all the possible isomers, 5 diastereoisomers, epimers, and geometric isomers, are included in the present disclosure.

The reaction reported under step 1) may be performed in a suitable solvent, in the presence of catalytic amounts, i.e. from 0.0001 to 0.2 molar equivalents, of a compound of formula



wherein

M represents Palladium, Nickel or Platinum.

L and L', which may be the same or different represent an anion such as, e.g. a halide or an acetate or a neutral 15 molecule such as, e.g., a solvent molecule, a phosphine, a phosphite or a diamine; and

q and r may vary from 0 to 4,

provided that $q + r$ is at least 1,

at a temperature of from about -20°C to about 200°C , 20 preferably from about 20°C to about 100°C , for a time which may vary from few minutes to several days, such as, e.g., from 5 minutes to 3 days, preferably from about one hour to about one day, optionally in the presence of a suitable organic or inorganic base, and optionally in the presence of lithium 25 halides, such as, e.g., LiCl, or LiBr.

Suitable solvents include, e.g., dimethylformamide (DMF), acetonitrile, dimethylsulphoxide (DMSO), CHCl_3 , dioxane, tetrahydrofuran (THF) and mixtures thereof.

Suitable inorganic bases include, e.g., salts with alkali or 30 alkaline earth metals, such as, for example, NaHCO_3 , Na_2CO_3 , or NaOAc.

Suitable organic bases may be, for example, trialkylamines, such as, e.g., triethylamine or diisopropylethylamine; or heteroaromatic bases such as, e.g., pyridine, or 2,6,-C₁-C₆ alkyl substituted pyridines, such as, e.g., 2,6 lutidine.

5 Preferred groups which L and/or L' may represent are halides; acetates; phosphines such as, e.g., triphenylphosphine or chelating diphosphines, such as, e.g., bis(diphenylphosphino)methane, 1,2- and 1,3-bis (diphenyl phosphino)propane, 1,4-bis(diphenylsphosphino)- butane or 1,1'-
10 bis(diphenylphosphino)ferrocene (DPPF).

The molar ratio of transition metal atom and/or is general from 1:1 to 1:4.

The reduction reported under item 2) may be performed reacting a compound of formula (I) as obtained under item 1) by using
15 suitable reducing agents, in the presence of suitable catalysts.

Suitable catalysts for the abovesaid reduction are metals known to perform multiple bond reduction such as, e.g., Palladium, Platinum oxide, Platinum, Rhodium, Nickel or
20 Ruthenium.

Suitable reducing agents for the abovesaid reduction are molecular hydrogen or hydrogen sources such as, for instance, triethylammonium formate, formic acid, tributyltin hydride, cyclohexadiene, etc., in a suitable solvent such as, e.g.,
25 dimethylformamide (DMF), CH₃OH, acetic acid, CHCl₃, dioxane, or mixtures thereof, at a temperature of from about 0°C to about 100°C, for a time of from 1 hour to 3 days, at a pressure of from about 1 atm to about 100 atm.

The starting materials used in this disclosure are known
30 compounds or may be obtained following known methods. For instance, 9-halogeno camptothecin, 10-halogeno camptothecin, 11-halogeno camptothecin, and 12-halogeno camptothecin may be

prepared according, to Sawada, S., et al., Chem. Pharm. Bull. 39, 3183-3188 (1991).

For instance, 10-hydroxy-9-halogeno camptothecin, 10-methoxy-9-halogeno camptothecin, and 10,11-methylenedioxy-9-halogeno camptothecin may be prepared starting from the corresponding 10 or 10,11 substituted 9-amino-derivatives, prepared by known procedures (see, for instance, Wall et al. J. Med. Chem. 1993, 36, 2689-2700, or Wani et al. J. Med. Chem. 1986, 29, 2358-2363), and then following the above cited reference.

- 10 For instance, 9-trifluoromethansulfonyloxy camptothecin, 10-trifluoromethansulfonyloxy camptothecin, 11-tri fluoro methansulfonyloxy camptothecin, 12-trifluoromethansulfonyloxy camptothecin, 10-hydroxy-9-trifluoromethansulfonyloxy camptothecin, 15 10-methoxy-9-trifluoromethansulfonyloxy camptothecin, 10,11-methylen-dioxy-9-trifluoromethansulfonyloxy camptothecin, 10-p-toluensulfonyloxy camptothecin, 11-p-toluensulfonyloxy camptothecin, 12-p-toluensulfonyloxy camptothecin, 20 10-hydroxy-9-p-toluensulfonyloxy camptothecin, 10-methoxy-9-p-toluensulfonyloxy camptothecin and 10,11-methylen-dioxy-9-p-toluensulfonyloxy camptothecin were prepared from the corresponding hydroxy derivatives obtained, in turn, as described in the references cited above, and 25 treatment with suitable sulfonylating agents.

The compounds of the present invention are endowed with antitumor activity, for example against leukaemia and solid tumors such as, for example, colon and rectal tumors.

- The antitumor activity of the compounds of the present invention is shown, for example, by the fact that they have 30 been found to possess antileukaemic activity when tested

according to the method described in: J.Med.Chem. 1993, 36, 2689, using the L1210 murine lymphoid leukemia model.

As an example, the activity of (E)-9-(2-methoxycarbonyl-ethenyl) camptothecin (internal code FCE 28681) and 9-(2-methoxycarbonyl-ethyl) camptothecin (internal code FCE 29559) were tested according to the following method (a).

The compounds were dissolved in dimethylsulfoxide (DMSO) at a final concentration of 0.5%. The percentage of DMSO solution does not affect the cellular growth.

10 Method (a): evaluation of cytotoxic activity

L1210 murine leukemia cells were grown in vitro as a floated cells in RPMI 1640 medium supplemented with 10% fetal calf serum, 1% L-glutamine 200 mM, 1% of B-mercaptoethanol 1 mM, 100 UI/ml penicillin and 100 µg streptomycin. For assaying the cytotoxic activity, exponentially growing cells were seeded at the concentration of 5×10^4 cells/ml and exposed to graded doses of the compounds under evaluation for 48h at 37°C in an humidified atmosphere of 5% CO₂. The number of surviving cells was determined with a Coulter Counter; results are expressed as IC₅₀ (dose causing 50% inhibition of cell growth in treated cultures relative to untreated controls after 48h treatment) in this assay, (E)-9-(2-methoxycarbonyl-ethenyl) camptothecin (internal code FCE 28681) and 9-(2-methoxycarbonyl-ethyl) camptothecin (internal code FCE 29559) were tested and the obtained results are reported on Table 1 below.

Table 1

COMPOUND	IC ₅₀ (ng/ml)
FCE 28681	3.3 ± 1.8
FCE 29559	2.7 ± 0.5

A human or animal body may thus be treated by a method which comprises the administration thereto of a pharmaceutically effective amount of a compound of formula (I) or salt thereof. The condition of the human or animal can thereby be improved.

- 5 Pharmaceutical compositions containing the novel camptothecin analogues according to the invention are also within the scope of the present invention.

These pharmaceutical compositions may contain any quantity of a camptothecin analog which is effective to exhibit any
10 antitumor activity in vivo. Mammalian such as humans are treatable with the inventive compositions. Typical in vivo doses within the scope of the invention are from 0.1-60 mg of camptothecin analog per kg of body weight. A particularly preferred range is 1-40 mg/kg.

- 15 There may also be included as part of the composition pharmaceutically compatible binding agents, and/or adjuvant materials. The active materials can also be mixed with other active materials which do not impair the desired action and/or supplement the desired action. The active materials according
20 to the present invention can be administered by any route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.

A preferred mode of administration of the compounds of the invention is oral.

- 25 Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the aforesaid compounds may be incorporated with excipients and used in the form of tablets, capsules,
30 elixirs, syrups and the like. These preparations should contain at least 0,1% of active compound but may be varied depending upon the particular form.

The tablets, pills, capsules, troches and the like may contain the following ingredients: a binder such as microcrystalline cellulose, gumtragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, corn starch and the like; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin or flavouring agent such as peppermint, methyl salicylate, or orange flavouring may be added. When the dosage unit form is a capsule, it may contain, in addition to material of the above type, a liquid carrier such as fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus tablets or pills may be coated with sugar shellac, or other enteric coating agents.

A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colouring and flavours.

Material used in preparing these various compositions should be pharmaceutically pure and non toxic in the amount used.

For the purpose of parenteral therapeutic administration, the active ingredient may be incorporated into a solution or suspension.

The solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulphite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The

parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

The dosage values will vary with the specific severity of the disease condition to be alleviated. Good results are achieved
5 when the compounds described herein are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose. It is to be understood that for any particular subject, specific dosage regimens should be adjusted to the individual need and the professional judgment
10 of the person administering or supervising the administration of the aforesaid compound. It is to be further understood that the dosages set forth herein are exemplary only and they do not limit the scope or practice of the invention. The dosages may be administered at once, or may be divided into a number
15 of smaller doses to be administered at varying intervals of time.

The following examples illustrates but do not limit the invention.

The number into bracket reported before the chemical name of
20 the compounds prepared according to the following examples corresponds to the number given to the preferred compounds listed on pages 6-18 of the present specification.

Preparation of the starting materials

25

Method A:

9-bromo camptothecin

2.15 g of NaNO_2 in 40 mL of H_2O were dropped at 5°C into a solution of 9 g of 9-amino-camptothecin in 850 mL of 16% HBr .
30 After 1 hr at r.t. the solution was dropped in a flask containing 19 g of CuBr in 200 mL of 16% HBr at 70°C . The reaction was allowed to stay at 70°C for 2 hr, then it was

poured in cold water. The precipitate was filtered and the mother liquors were extracted with CH_2Cl_2 ; the organic extract dried and evaporated was combined with the precipitate and purified by flash chromatography (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 95/5$) to give 8.19 g of the title product. (HPLC assay : 97.3%)

$^1\text{H-NMR}$ 400 MHz (DMSO-d_6): δ = 8.87 (s, 1H), 8.20 (d, $J = 8.5$, 1H), 8.06 (d, $J = 7.32$, 1H), 7.81-7.75 (m, 1H), 7.35 (s, 1H), 6.53 (s, 1H), 5.42 (s, 2H), 5.32 (s, 2H), 1.89-1.82 (m, 2H), 0.87 (t, $J = 7.32$, 3H).

MS (FD) : M^+ = 427.

By analogy starting from the corresponding amino derivatives, the following bromo derivatives were prepared:

10-bromo camptothecin;

11-bromo camptothecin;

12-bromo camptothecin;

10-hydroxy-9-bromo camptothecin;

10-methoxy-9-bromo camptothecin; and

10,11-methylenedioxy-9-bromo camptothecin.

20

Method B:

10-trifluoromethanesulfonyloxy camptothecin

1.25 g of 10-hydroxy camptothecin were dissolved in 35 mL of DMF and 2 mL of Et_3N and 1.5 g of N,N -Bis-(trifluoromethanesulfonyl)-anilin were added. The solution was heated at 50°C for 1 hr, then poured in water; the precipitate was filtered and the mother liquors were extracted with CH_2Cl_2 . The organic extract, dried (Na_2SO_4) and evaporated, was combined with the precipitate and purified by flash chromatography (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 98/2$). 1 g of the title product was obtained. (HPLC assay: 97%)

¹H-NMR 400 MHz (DMSO-d₆): δ = 8.81 (s, 1H), 8.43-8.32 (m, 2H), 7.99-7.94 (m, 1H), 7.36 (s, 1H), 6.54 (s, 1H), 5.42 (s, 2H), 5.32 (s, 2H), 1.90-1.81 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H).

5 MS (FD): M⁺ = 496

By analogy, starting from the corresponding nitro and amino derivatives, the following sulfonyl derivatives were prepared:

- 9-trifluoromethansulfonyloxy camptothecin;
- 10 11-trifluoromethansulfonyloxy camptothecin;
- 12-trifluoromethansulfonyloxy camptothecin;
- 10,11-methylenedioxy-9-trifluoromethansulfonyloxy camptothecin;
- 10-p-toluensulfonyloxy camptothecin;
- 11-p-toluensulfonyloxy camptothecin;
- 15 12-p-toluensulfonyloxy camptothecin;
- 10-methoxy-9-p-toluensulfonyloxy camptothecin; and
- 10,11-methylenedioxy-9-p-toluensulfonyloxy camptothecin.

Example 1

20 12-vinyl camptothecin (65)

1 g of 12-Br-camptothecin was dissolved in 20 mL of DMF; in an Ar atmosphere, 0.72 mL of Et₃N, 3.61 mL of vinyltrimethylsilane, 0.071 g of DPPF and 0.026 g of Pd(OAc)₂ were added sequentially. The reaction mixture was heated at
25 100°C for 1 hr and then treated with CH₂Cl₂ and water. The aqueous phase was extracted twice with CH₂Cl₂ and the organic extracts were collected, dried (Na₂SO₄), and evaporated. The residue was dissolved in 20 mL of CH₂Cl₂, 10 mL of CF₃COOH were added and the solution was left at r.t. for 24 hr. The
30 reaction was worked up as before and the product was purified by flash chromatography (eluent : CH₂Cl₂/CH₃OH = 95/5) to give 0.59 g of the title product. (HPLC assay : 97%).

¹H-NMR 400 MHz (DMSO-d₆): d = 8.67 (s, 1H), 8.14-8.00 (m, 3H), 7.69 (t, J=7.9Hz, 1H), 7.36 (s, 1H), 6.54 (s, 1H), 6.14 (dd, J=1.2, 17.9Hz, 1H), 5.57 (d, J=12.3Hz, 1H), 5.42 (s, 2H), 5.28 (s, 2H), 1.94-1.80 (m, 2H), 0.88 (t, J=7.0Hz, 3H).

5 MS (FD): M⁺ = 374.

By analogy the following compounds were obtained (Table 1):

- 9-vinyl camptothecin (1);
- 7-ethyl-9-vinyl camptothecin (9);
- 10 10-vinyl camptothecin (17);
- 7-ethyl-10-vinyl camptothecin (25);
- 10-hydroxy-9-vinyl camptothecin (33);
- 10,11-methylenedioxy-9-vinyl camptothecin (41);
- 10-methoxy-9-vinyl camptothecin (49);
- 15 11-vinyl camptothecin (57);
- 9-amino-10-vinyl camptothecin (73); and
- 7-ethyl-9-amino-10-vinyl camptothecin (81).

Example 2

- 20 (Z)-12-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin
(68)

2 g of 12-Br-camptothecin were dissolved in 40 mL of DMF; in an Ar atmosphere, 0.72 mL of Et₃N, 3.32 g of Methyl 2-acetamidoacrylate, 0.14 g of DPPF and 0.052 g of Pd(OAc)₂ were
25 added sequentially. The reaction mixture was heated at 100°C for 24 hr. The reaction mixture was cooled to room temperature, diluted with CH₂Cl₂ and washed with water. The organic extract was dried (Na₂SO₄) and the solvent removed under vacuo. The crude was purified by flash chromatography
30 (eluent : CH₂Cl₂/CH₃OH = 98/2) to give 1.72 g of the title product. (HPLC assay : 97.4%)

¹H-NMR 400 MHz (DMSO-d₆): δ = 9.79 (s, 1H), 8.73 (s, 1H),
8.32 (s, 1H), 8.18 (d, J = 7.03 Hz, 1H), 8.15 (d, J = 7.91 Hz,
1H), 7.75 (t, J = 7.62 Hz, 1H), 7.34 (s, 1H), 6.56 (s, 1H),
5.43 (s, 2H), 5.43 (s, 2H), 3.78 (s, 3H), 1.98 (s, 3H), 1.88
5 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H).

MS (FD) : M⁺ = 489.

When a solution of (Z)-12-(2-acetylamino-2-methoxycarbonyl-
ethenyl) camptothecin is allowed to stand at room temperature
10 for 2 weeks, a 50/50 mixture of E and Z isomers is obtained.

By analogy the following compounds were obtained (Table 1):

- 10-(2-acetylamino-2-methoxycarbonyl-ethenyl) camptothecin
(20);
- 15 10-(2-acetylamino-2-hydroxycarbonyl-ethenyl) camptothecin
(21);
- 7-ethyl-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (28);
- 7-ethyl-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
20 camptothecin (29);
- 10-hydroxy-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (36);
- 10-hydroxy-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (37);
- 25 10,11-methylenedioxy-9-(2-acetylamino-2-methoxycarbonyl-
ethenyl) camptothecin (44);
- 10,11-methylenedioxy-9-(2-acetylamino-2-hydroxycarbonyl-
ethenyl) camptothecin (45);
- 10-methoxy-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)
30 camptothecin (52);
- 10-methoxy-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (53);

- 11-(2-acetylamino-2-methoxycarbonyl-ethenyl) camptothecin
(60);
11-(2-acetylamino-2-hydroxycarbonyl-ethenyl) camptothecin
(61);
5 12-(2-acetylamino-2-hydroxycarbonyl-ethenyl) camptothecin
(69);
9-amino-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (76);
9-amino-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
10 camptothecin (77);
7-ethyl-9-amino-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (84); and
7-ethyl-9-amino-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (85).

15

Example 3(E)-12-(2-methoxycarbonyl-ethenyl) camptothecin (66)

- 5 g of 12-Br-camptothecin were dissolved in 50 mL of DMF; in
an Ar atmosphere, 1.5 mL of Et₃N, 4.6 mL of Methyl acrylate,
20 0.28 g of DPPF and 0.11 g of Pd(OAc)₂ were added sequentially.
The reaction was heated at 100°C for 18 hr then worked up
diluting with CH₂Cl₂ and washing twice with water. The organic
phase was dried (Na₂SO₄) evaporated and the residue was
purified by flash chromatography (eluent: CH₂Cl₂/CH₃OH = 98/2)
25 to give 4.1 g of the title product. (HPLC assay : 92.34%)
¹H-NMR 400 MHz (DMSO-d₆) : d = 8.94 (d, J = 16.2 Hz, 1H), 8.73
(s, 1H), 8.39 (d, J = 6.7 Hz, 1H), 8.21 (d, J = 8.2 Hz, 1H),
7.75 (t, J = 7.6, 1H), 7.36 (s, 1H), 7.00 (d, J = 16.2 Hz,
1H), 6.59 (s, 1H), 5.43 (s, 2H), 5.30 (s, 2H), 3.80 (s, 3H),
30 1.88 (m, 2H), 0.89 (t, 3H).
MS (FD) : M⁺ = 432.

By analogy the following compounds were obtained (Table 1):

- 11-(2-methoxycarbonyl-ethenyl) camptothecin (58);
11-(2-hydroxycarbonyl-ethenyl) camptothecin (59);
11-(3-oxo-but-1-enyl) camptothecin (62);
5 11-(3-oxo-3-phenyl-propenyl) camptothecin (63);
11-(2-aminocarbonyl-ethenyl) camptothecin (64);
12-(2-hydroxycarbonyl-ethenyl) camptothecin (67);
12-(3-oxo-but-1-enyl) camptothecin (70);
12-(3-oxo-3-phenyl-propenyl) camptothecin (71);
10 12-(2-aminocarbonyl-ethenyl) camptothecin (72);
9-amino-10-(2-methoxycarbonyl-ethenyl) camptothecin (74);
9-amino-10-(2-hydroxycarbonyl-ethenyl) camptothecin (75);
9-amino-10-(3-oxo-but-1-enyl) camptothecin (78);
9-amino-10-(3-oxo-3-phenyl-propenyl) camptothecin (79);
15 9-amino-10-(2-aminocarbonyl-ethenyl) camptothecin (80);
7-ethyl-9-amino-10-(2-methoxycarbonyl-ethenyl) camptothecin
(82);
7-ethyl-9-amino-10-(2-hydroxycarbonyl-ethenyl) camptothecin
(83);
20 7-ethyl-9-amino-10-(3-oxo-but-1-enyl) camptothecin (86);
7-ethyl-9-amino-10-(3-oxo-3-phenyl-propenyl) camptothecin
(87); and
7-ethyl-9-amino-10-(2-aminocarbonyl-ethenyl) camptothecin
(88).

25

Example 4

12-(2-methoxycarbonyl-ethyl) camptothecin (52')

- 1 g of 12-(2-methoxycarbonyl-ethenyl) camptothecin was
dissolved in 20 mL of DMF and hydrogenated in presence of 0.1
30 g of Pd/C at r.t. under 1 atm of H₂. The reaction mixture was
filtered through a celite pad washing the celite thoroughly
with DMF, the solvent was evaporated and the residue was

purified by flash chromatography (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH} = 98/2$) to give 0.82 g of the title product.

^1H -NMR 400 MHz (DMSO- d_6) : δ = 8.60 (s, 1H), 7.92 (dd, J = 1.5, 8.2 Hz, 1H), 7.66 (dd, J = 1.5, 7 Hz, 1H), 7.54 (dd, J = 7, 8.2 Hz, 1H), 7.31 (s, 1H), 6.54 (s, 1H), 5.41 (s, 2H), 5.20 (m, 2H), 3.57 (s, 3H), 3.52-3.49 (m, 2H), 2.84-2.81 (m, 2H), 1.88-1.84 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H). MS (FD) : M^+ = 434.

- 10 By analogy the following compounds were obtained (Table 2):
- 11-ethyl camptothecin (41');
 - 11-(2-methoxycarbonyl-ethyl) camptothecin (42');
 - 11-(2-hydroxycarbonyl-ethyl) camptothecin (43');
 - 11-(3-oxo-butyl) camptothecin (48');
 - 15 11-(3-oxo-3-phenyl-propyl) camptothecin (49');
 - 11-(2-aminocarbonyl-ethyl) camptothecin (50');
 - 9-amino-12-ethyl camptothecin (51');
 - 9-amino-12-(2-methoxycarbonyl-ethyl) camptothecin (52');
 - 9-amino-12-(2-hydroxycarbonyl-ethyl) camptothecin (53');
 - 20 9-amino-12-(3-oxo-butyl) camptothecin (58');
 - 9-amino-12-(3-oxo-3-phenyl-propyl) camptothecin (59');
 - 9-amino-12-(2-aminocarbonyl-ethyl) camptothecin (60');
 - 10-amino-9-ethyl camptothecin (61');
 - 10-amino-9-(2-methoxycarbonyl-ethyl) camptothecin (62');
 - 25 10-amino-9-(2-hydroxycarbonyl-ethyl) camptothecin (63');
 - 10-amino-9-(3-oxo-butyl) camptothecin (68');
 - 10-amino-9-(3-oxo-3-phenyl-3-one-propyl) camptothecin (69');
 - 10-amino-9-(2-aminocarbonyl-ethyl) camptothecin (70');
 - 12-ethyl camptothecin (71');
 - 30 12-(2-hydroxycarbonyl-ethyl) camptothecin (73');
 - 12-(3-oxo-butyl) camptothecin (78');
 - 12-(3-oxo-3-phenyl-propyl) camptothecin (79');

- 12-(2-aminocarbonyl-ethyl) camptothecin (80');
10-hydroxy-9-ethyl camptothecin (81');
10-hydroxy-9-(2-methoxycarbonyl-ethyl) camptothecin (82');
10-hydroxy-9-(2-hydroxycarbonyl-ethyl) camptothecin (83');
5 10-hydroxy-9-(3-oxo-butyl) camptothecin (88');
10-hydroxy-9-(3-oxo-3-phenyl-3-one-propyl) camptothecin (89');
10-hydroxy-9-(2-aminocarbonyl-ethyl) camptothecin (90');
10-methoxy-9-ethyl camptothecin (101');
10-methoxy-9-(2-methoxycarbonyl-ethyl) camptothecin (102');
10 10-methoxy-9-(2-hydroxycarbonyl-ethyl) camptothecin (103');
10-methoxy-9-(3-oxo-butyl) camptothecin (108');
10-methoxy-9-(3-oxo-3-phenyl-propyl) camptothecin (109'); and
10-methoxy-9-(2-aminocarbonyl-ethyl) camptothecin (110').

15 Example 5

12-[(2R,S)(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (74')

- 1 g of (Z)-12-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin was dissolved in DMF. After addition of 0.15 g of
20 Pd/C, the product was hydrogenated at r.t. for 28 hr. The
reaction mixture was filtered through a pad of celite and
evaporated; the residue was purified by flash chromatography
(eluent: CH₂Cl₂/CH₃OH) to give 0.89 g of the title product.
(HPLC assay : 96.7%)

- 25 ¹H-NMR 400 MHz (DMSO-d₆) : δ = 8.66 (s, 1H), 8.49-8.43 (m,
1H), 7.99 (d, J = 7.33 Hz, 1H), 7.63-7.60 (m, 2H), 7.42 (s,
1/2H), 7.40 (s, 1/2H), 6.56 (s, 1/2H), 6.54 (s, 1/2H), 5.42
(s, 2H), 5.30 (s, 2H), 4.75-4.66 (m, 1H), 3.96-3.88 (m, 1H),
3.55 (s, 1.5H), 3.49 (s, 1.5H), 3.36-3.31 (m, 1H), 1.81-1.87
30 (m, 2H), 1.77 (s, 1.5H), 1.75 (s, 1.5H), 0.92-0.94 (m, 3H).

MS (FD) : M⁺ = 491

By analogy the following compounds may be obtained (Table 2):

- 9-[(2-acetylamino-2-methoxycarbonyl)-ethyl] camptothecin (4');
9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (5');
9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (6');
9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin (7');
5 7-ethyl-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (14');
7-ethyl-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(15');
7-ethyl-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
10 (16');
7-ethyl-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (17');
10-[(2-acetylamino-2-methoxycarbonyl)-ethyl] camptothecin
(24');
15 10-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (25');
10-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (26');
10-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin
(27');
7-ethyl-10-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
20 camptothecin (34');
7-ethyl-10-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(35');
7-ethyl-10-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
(36');
25 7-ethyl-10-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (37');
11-[(2-acetylamino-2-methoxycarbonyl)-ethyl] camptothecin
(44');
11-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (45');
30 11-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (46');
11-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin
(47');

- 9-amino-12-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (54');
9-amino-12-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(55');
5 9-amino-12-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
(56');
9-amino-12-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (57');
10-amino-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
10 camptothecin (64');
10-amino-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(65');
10-amino-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
(66');
15 10-amino-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (67');
12-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (75');
12-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (76');
12-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin
20 (77');
10-hydroxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (84');
10-hydroxy-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(85');
25 10-hydroxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
(86');
10-hydroxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (87');
10,11-methylenedioxy-9-[(2-acetylamino-2-methoxycarbonyl)-
30 ethyl]-camptothecin (94');
10,11-methylenedioxy-9-[(2-amino-2-methoxycarbonyl)-ethyl]
camptothecin (95');

10,11-methylenedioxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl]
camptothecin (96');

10,11-methylenedioxy-9-[(2-acetylamino-2-hydroxycarbonyl)-
ethyl]-camptothecin (97');

5 10-methoxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (104');

10-methoxy-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(105');

10-methoxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
10 (106'); and

10-methoxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (107').

Example 7

15 (Z)-9-(2-acetylamino-2-methoxycarbonyl-ethenyl) camptothecin
(4)

5 g of 9-Br-camptothecin were dissolved in 50 mL of DMF; in an
Ar atmosphere, 1.8 mL of Et₃N, 8.3 g of Methyl 2-
acetamidoacrylate, 0.35 g of DPPF and 0.13 g of Pd(OAc)₂ were
20 added sequentially. The reaction mixture was heated at 100°C
for 7 hr and then taken up with CH₂Cl₂ and water. The organic
extract was dried (Na₂SO₄), the solvent was evaporated and the
residue was purified by flash chromatography (eluent:
CH₂Cl₂/CH₃OH = 98/2) to give 4.89 g of the title product. (HPLC
25 assay : 98.7%)

¹H-NMR 400 MHz (DMSO-d₆) : δ = 9.63 (s, 1H), 8.73 (s, 1H),
8.16 (d, J = 8.54 Hz, 1H), 7.89-7.85 (m, 1H), 7.77 (d, J =
7.26, 1H), 7.62 (s, 1H), 7.34 (s, 1H), 6.52 (s, 1H), 5.41 (s,
2H), 5.25 (s, 2H), 3.76 (s, 3H), 1.87-1.83 (m, 5H), 0.86 (t,
30 J = 7.26, 3H).

MS (FD) : M⁺ = 489

When a solution of (Z)-9-(2-acetylamino-2-methoxycarbonyl-ethenyl) camptothecin is allowed to stand at r.t. for 2 weeks, a 50/50 mixture of E and Z isomers is obtained. The ¹H-NMR spectrum of (E)-9-(2-acetylamino-2-methoxycarbonyl-ethenyl) camptothecin is:

δ = 10.32 (s, 1H), 8.74 (s, 1H), 8.09 (d, J = 8.79, 1H), 7.80-7.76 (m, 1H), 7.63 (s, 1H), 7.37-7.34 (m, 2H), 6.53 (s, 1H), 5.42 (s, 2H), 5.28 (s, 2H), 3.42 (s, 3H), 2.02 (s, 3H), 1.89-1.82 (m, 2H), 0.87 (t, J = 7.26, 3H).

10

By analogy the following compounds were prepared (Table 1):

9-(2-acetylamino-2-hydroxycarbonyl-ethenyl) camptothecin (5);

7-ethyl-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)

camptothecin (12); and

15

7-ethyl-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)

camptothecin (13).

Example 8

(E)-9-(2-methoxycarbonyl-ethenyl) camptothecin (2)

20 1 g of 9-Br-camptothecin was dissolved in 11 mL of DMF; 0.3 mL of Et₃N, 0.92 mL of Methyl acrylate, 0.056 g of DPPF, 0.022 g of Pd(OAc)₂ were added sequentially under an Ar atmosphere. The reaction mixture was heated at 100°C; after 3 hr the reaction is over and a white yellowish precipitate is present. The precipitate is filtered and washed twice with DMF and twice with Et₂O. The product is crystallized (CHCl₃/DMF) to give 0.58 g of the title product. (HPLC assay : 95.59%)

¹H-NMR 400 MHz (DMSO-d₆) : δ = 9.07 (s, 1H), 8.45 (d, J = 15.5 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 8.14 (d, J = 7.1, 1H), 7.88 (dd, J = 7.6 Hz, J' = 8.2 Hz, 1H), 7.34 (s, 1H), 6.80 (d, J =

30

15.8 Hz, 1H), 6.53 (s, 1H), 5.42 (s, 2H), 5.27 (s, 2H), 3.79 (s, 3H), 1.86 (m, 2H), 0.87 (t, 3H).

MS (FD) : M^+ = 432.

- 5 By analogy the following compounds were prepared (Table 1):
- 9-(2-hydroxycarbonyl-ethenyl) camptothecin (3);
- 9-(2-aminocarbonyl-ethenyl) camptothecin (8);
- 9-(3-oxo-but-1-enyl) camptothecin (6);
- 9-(3-oxo-3-phenyl-propenyl) camptothecin (7);
- 10 7-ethyl-9-(2-methoxycarbonyl-ethenyl) camptothecin (10);
- 7-ethyl-9-(2-hydroxycarbonyl-ethenyl) camptothecin (11);
- 7-ethyl-9-(3-oxo-but-1-enyl) camptothecin (14);
- 7-ethyl-9-(3-oxo-3-phenyl-propenyl) camptothecin (15);
- 7-ethyl-9-(2-aminocarbonyl-ethenyl) camptothecin (16);
- 15 10,11-methylenedioxy-9-(2-methoxycarbonyl-ethenyl) camptothecin (42);
- d10,11-methylenedioxy-9-(2-hydroxycarbonyl-ethenyl) camptothecin (43);
- 10,11-methylenedioxy-9-(3-oxo-but-1-enyl) camptothecin (46);
- 20 10,11-methylenedioxy-9-(3-oxo-3-phenyl-propenyl) camptothecin (47);
- 10,11-methylenedioxy-9-(2-aminocarbonyl-ethenyl) camptothecin (48);
- 10-methoxy-9-(2-methoxycarbonyl-ethenyl) camptothecin 50);
- 25 10-methoxy-9-(2-hydroxycarbonyl-ethenyl) camptothecin (51);
- 10-methoxy-9-(3-oxo-but-1-enyl) camptothecin (54);
- 10-methoxy-9-(3-oxo-3-phenyl-propenyl) camptothecin (55); and
- 10-methoxy-9-(2-aminocarbonyl-ethenyl) camptothecin (56).

30 Example 9

9-(2-methoxycarbonyl-ethyl) camptothecin (2')

1.4 g of (E)-9-(2-methoxycarbonyl-ethenyl) camptothecin are dissolved in 400 mL of DMF, 0.3 g of Pd/C are added and the mixture is hydrogenated at r.t. (1 atm H₂) for 3 hr. The reaction mixture is filtered and the solvent is evaporated.

5 The residue is purified by flash chromatography (eluent : CH₂Cl₂/CH₃OH = 98/2) to give 1.2 g of the title product.

¹H-NMR 400 MHz (DMSO-d₆) : δ = 8.89 (s, 1H), 8.03 (d, J = 8.49 Hz, 1H), 7.79-7.73 (m, 1H), 7.55 (d, J = 7.03, 1H), 7.33 (s, 1H), 6.51 (s, 1H), 5.42 (s, 2H), 5.28 (s, 2H), 3.59 (s, 10 3H), 3.42-3.36 (m, 2H), 2.88-2.77 (m, 2H), 1.91-1.80 (m, 2H), 0.87 (t, J = 7.33, 3H).

MS (FD) : M⁺ = 434.

By analogy the following compounds were prepared (Table 2):

- 15 9-ethyl camptothecin (1');
9-(2-hydroxycarbonyl-ethyl) camptothecin (3');
9-(3-oxo-butyl) camptothecin (8');
9-(3-oxo-3-phenyl--propyl) camptothecin (9');
9-(2-aminocarbonyl-ethyl) camptothecin (10');
20 7-ethyl-9-ethyl camptothecin (11');
7-ethyl-9-(2-methoxycarbonyl-ethyl) camptothecin (12');
7-ethyl-9-(2-hydroxycarbonyl-ethyl) camptothecin (13');
7-ethyl-9-(3-oxo-butyl) camptothecin (18');
7-ethyl-9-(3-oxo-3-phenyl-propyl) camptothecin (19');
25 7-ethyl-9-(2-aminocarbonyl-ethyl) camptothecin (20');
10-ethyl camptothecin (21');
10-(2-methoxycarbonyl-ethyl) camptothecin (22');
10-(2-hydroxycarbonyl-ethyl) camptothecin (23');
10-(3-oxo-butyl) camptothecin (28');
30 10-(3-oxo-3-phenyl-propyl) camptothecin (29');
10-(2-aminocarbonyl-ethyl) camptothecin (30');
7-ethyl-10-ethyl camptothecin (31');

7-ethyl-10-(2-methoxycarbonyl-ethyl) camptothecin (32');
7-ethyl-10-(2-hydroxycarbonyl-ethyl) camptothecin (33');
7-ethyl-10-(3-oxo-butyl) camptothecin (38');
7-ethyl-10-(3-oxo-3-phenyl-propyl) camptothecin (39');
5 7-ethyl-10-(2-aminocarbonyl-ethyl) camptothecin (40');
10,11-methylenedioxy-9-ethyl camptothecin (91');
10,11-methylenedioxy-9-(2-methoxycarbonyl-ethyl) camptothecin
(92');
10,11-methylenedioxy-9-(2-hydroxycarbonyl-ethyl) camptothecin
10 (93');
10,11-methylenedioxy-9-(3-oxo-butyl) camptothecin (98');
10,11-methylenedioxy-9-(3-oxo-3-phenyl-propyl) camptothecin
(99'); and
10,11-methylenedioxy-9-(2-aminocarbonyl-ethyl) camptothecin
15 (100').

Example 10

(E)-10-(2-methoxycarbonyl-ethenyl) camptothecin (18)

1 g of 10-trifluoromethansulfonyloxy camptothecin was
20 dissolved in 10 mL of DMF; in an Ar atmosphere, 0.31 mL of
Et₃N, 0.91 mL of Methyl acrylate, 0.062 g of DPPF and 0.023 g
of Pd(OAc)₂ were added sequentially. The reaction was heated
at 80°C for 24 hr then worked up diluting with CH₂Cl₂ and
washing twice with brine. The organic phase was dried (Na₂SO₄)
25 evaporated and the residue was purified by flash
chromatography (eluent: CH₂Cl₂/CH₃OH = 99/1) to give 0.5 g of
the title product. (HPLC assay : 97%)
¹H-NMR 400 MHz (DMSO-d₆) : δ = 8.65 (s, 1H), 8.42 (s, 1H),
8.24 (d, J = 9.0 Hz, 1H), 8.14 (d, J = 9.0 Hz, 1H), 7.86 (d,
30 J = 16.1 Hz, 1H), 7.34 (s, 1H), 6.87 (d, J = 16.1 Hz, 1H),
6.53 (s, 1H), 5.41 (s, 2H), 5.28 (s, 2H), 3.76 (s, 3H), 1.88-
1.82 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H).


MS (FD) : M^+ = 432.

By analogy the following compounds were prepared (Table 1):

- 10-(2-hydroxycarbonyl-ethenyl) camptothecin (19);
- 5 10-(3-oxo-but-1-enyl) camptothecin (22);
- 10-(3-oxo-3-phenyl-propenyl) camptothecin (23);
- 10-(2-aminocarbonyl-ethenyl) camptothecin (24);
- 7-ethyl-10-(2-methoxycarbonyl-ethenyl) camptothecin (26);
- 7-ethyl-10-(2-hydroxycarbonyl-ethenyl) camptothecin (27);
- 10 7-ethyl-10-(3-oxo-but-1-enyl) camptothecin (30);
- 7-ethyl-10-(3-oxo-3-phenyl-propenyl) camptothecin (31);
- 7-ethyl-10-(2-aminocarbonyl-ethenyl) camptothecin (32);
- 10-hydroxy-9-(2-methoxycarbonyl-ethenyl) camptothecin (34);
- 10-hydroxy-9-(2-hydroxycarbonyl-ethenyl) camptothecin (35);
- 15 10-hydroxy-9-(3-oxo-but-1-enyl) camptothecin (38);
- 10-hydroxy-9-(3-oxo-3-phenyl-propenyl) camptothecin (39); and
- 10-hydroxy-9-(2-aminocarbonyl-ethenyl) camptothecin (40).

CLAIMS

1. Substituted camptothecin derivatives of formula (I)



5 wherein

the symbol ---- represents a single or double bond;

R₁, R₂ and R₃ are as defined under (a) or (b) below:

(a) R₁ and R₂ are, each independently,

hydrogen;


10 C₁-C₄ alkyl;

C₃-C₇ cycloalkyl;

phenyl C₁-C₆ alkyl;

an optionally substituted phenyl ring;

-NR₅R₆ wherein one of R₅ and R₆ is hydrogen, C₁-C₆ alkyl or
 15 benzyl and the other is hydrogen, C₁-C₆ alkanoyl, an
 optionally substituted C₁-C₆ alkoxy carbonyl, an optionally
 substituted benzoyl, phenyl C₁-C₆ alkanoyl, an optionally
 substituted phenoxy carbonyl or phenyl C₁-C₆
 alkoxy carbonyl, or R₅ and R₆, combined together with the
 20 nitrogen atom to which they are linked, form a 4-7
 membered saturated, optionally substituted,
 heteromonocyclic ring residue, represented by a group (G)



wherein W is -C=O, R₇ is hydrogen or C₁-C₆ alkyl and n is
 25 an integer of 2 to 5;

- COOR₈ wherein R₈ is hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or phenyl C₁-C₆ alkyl; or
- COR₉ wherein R₉ is C₁-C₆ alkyl, C₃-C₇ cycloalkyl, phenyl C₁-C₆ alkyl, an optionally substituted phenyl ring or
- 5 NR₁₀R₁₁ wherein R₁₀ and R₁₁ are, each independently, hydrogen or C₁-C₆ alkyl; and
- R₃ is hydrogen, C₁-C₆ alkyl or an optionally substituted phenyl ring; or
- (b) R₁ and R₃, combined together, form a 5-8 membered, optionally substituted, carbomonocyclic ring; and
- 10 R₂ is hydrogen, C₁-C₄ alkyl or C₃-C₇ cycloalkyl;
- R₄ is hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or phenyl C₁-C₆ alkyl;
- X is hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, C₃-C₇ cycloalkoxy, C₁-C₆ alkanoyloxy, benzoyloxy, amino, hydroxy, nitro, halogen or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof.
- 15
- 20 2. A compound of formula (I), according to claim 1, wherein the symbol ---- represents a single or a double bond;
- R₁ and R₂ are, each independently, hydrogen;
- NR₅R₆ wherein one of R₅ and R₆ is hydrogen and the other is
- 25 hydrogen C₁-C₆ alkanoyl, an optionally substituted benzoyl, phenyl C₁-C₆ alkanoyl, C₁-C₆ alkoxy-carbonyl, phenoxy-carbonyl or phenyl C₁-C₆ alkoxy-carbonyl;
- COOR₈ wherein R₈ is hydrogen or C₁-C₆ alkyl; or
- COR₉ wherein R₉ is C₁-C₆ alkyl, unsubstituted phenyl or NR₁₀R₁₁
- 30 wherein R₁₀ and R₁₁ are both hydrogen;
- R₃ is hydrogen;
- R₄ is hydrogen or C₁-C₆ alkyl;

X is hydrogen, hydroxy, amino, C₁-C₆ alkoxy or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof.

- 5 3. A compound selected from:
- 9-vinyl camptothecin (1);
- (E)-9-(2-methoxycarbonyl-ethenyl)camptothecin (2);
- 9-(2-hydroxycarbonyl-ethenyl)camptothecin (3);
- (Z)-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin
- 10 (4);
- 9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (5);
- 9-(3-oxo-but-1-enyl)camptothecin (6);
- 9-(3-oxo-3-phenyl-propenyl)camptothecin (7);
- 9-(2-aminocarbonyl-ethenyl)camptothecin (8);
- 15 7-ethyl-9-vinyl camptothecin (9);
- 7-ethyl-9-(2-methoxycarbonyl-ethenyl)camptothecin (10);
- 7-ethyl-9-(2-hydroxycarbonyl-ethenyl)camptothecin (11);
- 7-ethyl-9-(2-acetylamino-2-methoxycarbonyl-
- ethenyl)camptothecin (12);
- 20 7-ethyl-9-(2-acetylamino-2-hydroxycarbonyl-
- ethenyl)camptothecin (13);
- 7-ethyl-9-(3-oxo-but-1-enyl)camptothecin (14);
- 7-ethyl-9-(3-oxo-3-phenyl-propenyl)camptothecin (15);
- 7-ethyl-9-(2-aminocarbonyl-ethenyl)camptothecin (16);
- 25 10-vinyl camptothecin (17);
- (E)-10-(2-methoxycarbonyl-ethenyl)camptothecin (18);
- 10-(2-hydroxycarbonyl-ethenyl)camptothecin (19);
- 10-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (20);
- 10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (21);
- 30 10-(3-oxo-but-1-enyl)camptothecin (22);
- 10-(3-oxo-3-phenyl-propenyl)camptothecin (23);
- 10-(2-aminocarbonyl-ethenyl)camptothecin (24);

- 7-ethyl-10-vinyl camptothecin (25);
7-ethyl-10-(2-methoxycarbonyl-ethenyl) camptothecin (26);
7-ethyl-10-(2-hydroxycarbonyl-ethenyl) camptothecin (27);
7-ethyl-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
5 camptothecin (28);
7-ethyl-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (29);
7-ethyl-10-(3-oxo-but-1-enyl) camptothecin (30);
7-ethyl-10-(3-oxo-3-phenyl-propenyl) camptothecin (31);
10 7-ethyl-10-(2-aminocarbonyl-ethenyl) camptothecin (32);
10-hydroxy-9-vinyl camptothecin (33);
10-hydroxy-9-(2-methoxycarbonyl-ethenyl) camptothecin (34);
10-hydroxy-9-(2-hydroxycarbonyl-ethenyl) camptothecin (35);
10-hydroxy-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)
15 camptothecin (36);
10-hydroxy-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (37);
10-hydroxy-9-(3-oxo-but-1-enyl) camptothecin (38);
10-hydroxy-9-(3-oxo-3-phenyl-propenyl) camptothecin (39);
20 10-hydroxy-9-(2-aminocarbonyl-ethenyl) camptothecin (40);
10,11-methylenedioxy-9-vinyl camptothecin (41);
10,11-methylenedioxy-9-(2-methoxycarbonyl-ethenyl) camptothecin
(42);
10,11-methylenedioxy-9-(2-hydroxycarbonyl-ethenyl) camptothecin
25 (43);
10,11-methylenedioxy-9-(2-acetylamino-2-methoxycarbonyl-
ethenyl) camptothecin (44);
10,11-methylenedioxy-9-(2-acetylamino-2-hydroxycarbonyl-
ethenyl) camptothecin (45);
30 10,11-methylenedioxy-9-(3-oxo-but-1-enyl) camptothecin (46);
10,11-methylenedioxy-9-(3-oxo-3-phenyl-propenyl) camptothecin
(47);

- 10,11-methylenedioxy-9-(2-aminocarbonyl-ethenyl)camptothecin (48);
- 10-methoxy-9-vinyl camptothecin (49);
- 10-methoxy-9-(2-methoxycarbonyl-ethenyl)camptothecin (50);
- 5 10-methoxy-9-(2-hydroxycarbonyl-ethenyl)camptothecin (51);
- 10-methoxy-9-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (52);
- 10-methoxy-9-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (53);
- 10 10-methoxy-9-(3-oxo-but-1-enyl)camptothecin (54);
- 10-methoxy-9-(3-oxo-3-phenyl-propenyl)camptothecin (55);
- 10-methoxy-9-(2-aminocarbonyl-ethenyl)camptothecin (56);
- 11-vinyl camptothecin (57);
- 11-(2-methoxycarbonyl-ethenyl)camptothecin (58);
- 15 11-(2-hydroxycarbonyl-ethenyl)camptothecin (59);
- 11-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin (60);
- 11-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (61);
- 11-(3-oxo-but-1-enyl)camptothecin (62);
- 11-(3-oxo-3-phenyl-propenyl)camptothecin (63);
- 20 11-(2-aminocarbonyl-ethenyl)camptothecin (64);
- 12-vinyl camptothecin (65);
- (E)-12-(2-methoxycarbonyl-ethenyl)camptothecin (66);
- 12-(2-hydroxycarbonyl-ethenyl)camptothecin (67);
- (Z)-12-(2-acetylamino-2-methoxycarbonyl-ethenyl)camptothecin
- 25 (68);
- 12-(2-acetylamino-2-hydroxycarbonyl-ethenyl)camptothecin (69);
- 12-(3-oxo-but-1-enyl)camptothecin (70);
- 12-(3-oxo-3-phenyl-propenyl)camptothecin (71);
- 12-(2-aminocarbonyl-ethenyl)camptothecin (72);
- 30 9-amino-10-vinyl camptothecin (73);
- 9-amino-10-(2-methoxycarbonyl-ethenyl)camptothecin (74);
- 9-amino-10-(2-hydroxycarbonyl-ethenyl)camptothecin (75);

- 9-amino-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (76);
- 9-amino-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (77);
- 5 9-amino-10-(3-oxo-but-1-enyl)camptothecin (78);
- 9-amino-10-(3-oxo-3-phenyl-propenyl)camptothecin (79);
- 9-amino-10-(2-aminocarbonyl-ethenyl)camptothecin (80);
- 7-ethyl-9-amino-10-vinyl camptothecin (81);
- 7-ethyl-9-amino-10-(2-methoxycarbonyl-ethenyl)camptothecin
10 (82);
- 7-ethyl-9-amino-10-(2-hydroxycarbonyl-ethenyl)camptothecin
(83);
- 7-ethyl-9-amino-10-(2-acetylamino-2-methoxycarbonyl-ethenyl)
camptothecin (84);
- 15 7-ethyl-9-amino-10-(2-acetylamino-2-hydroxycarbonyl-ethenyl)
camptothecin (85);
- 7-ethyl-9-amino-10-(3-oxo-but-1-enyl)camptothecin (86);
- 7-ethyl-9-amino-10-(3-oxo-3-phenyl-propenyl)camptothecin (87);
- 7-ethyl-9-amino-10-(2-aminocarbonyl-ethenyl)camptothecin (88);
- 20 9-ethyl camptothecin (1');
- 9-(2-methoxycarbonyl-ethyl)camptothecin (2');
- 9-(2-hydroxycarbonyl-ethyl)camptothecin (3');
- 9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin (4');
- 9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (5');
- 25 9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (6');
- 9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (7');
- 9-(3-oxo-butyl)camptothecin (8');
- 9-(3-oxo-3-phenyl-propyl)camptothecin (9');
- 9-(2-aminocarbonyl-ethyl)camptothecin (10');
- 30 7-ethyl-9-ethyl camptothecin (11');
- 7-ethyl-9-(2-methoxycarbonyl-ethyl)camptothecin (12');
- 7-ethyl-9-(2-hydroxycarbonyl-ethyl)camptothecin (13');

- 7-ethyl-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (14');
7-ethyl-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
(15');
5 7-ethyl-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
(16');
7-ethyl-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (17');
7-ethyl-9-(3-oxo-butyl) camptothecin (18');
10 7-ethyl-9-(3-oxo-3-phenyl-propyl) camptothecin (19');
7-ethyl-9-(2-aminocarbonyl-ethyl) camptothecin (20');
10-ethyl camptothecin (21');
10-(2-methoxycarbonyl-ethyl) camptothecin (22');
10-(2-hydroxycarbonyl-ethyl) camptothecin (23');
15 10-[(2-acetylamino-2-methoxycarbonyl)-ethyl] camptothecin
(24');
10-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (25');
10-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (26');
10-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin (27');
20 10-(3-oxo-butyl) camptothecin (28');
10-(3-oxo-3-phenyl-propyl) camptothecin (29');
10-(2-aminocarbonyl-ethyl) camptothecin (30');
7-ethyl-10-ethyl camptothecin (31');
7-ethyl-10-(2-methoxycarbonyl-ethyl) camptothecin (32');
25 7-ethyl-10-(2-hydroxycarbonyl-ethyl) camptothecin (33');
7-ethyl-10-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (34');
7-ethyl-10-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin
35');
30 7-ethyl-10-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin
36');

- 7-ethyl-10-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (37');
7-ethyl-10-(3-oxo-butyl)camptothecin (38');
7-ethyl-10-(3-oxo-3-phenyl-propyl)camptothecin (39');
5 7-ethyl-10-(2-aminocarbonyl-ethyl)camptothecin (40');
11-ethyl camptothecin (41');
11-(2-methoxycarbonyl-ethyl)camptothecin (42');
11-(2-hydroxycarbonyl-ethyl)camptothecin (43');
11-[(2-acetylamino-2-methoxycarbonyl)-ethyl]camptothecin
10 (44');
11-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (45');
11-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (46');
11-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin
(47');
15 11-(3-oxo-butyl)camptothecin (48');
11-(3-oxo-3-phenyl-propyl)camptothecin (49');
11-(2-aminocarbonyl-ethyl)camptothecin (50');
9-amino-12-ethyl camptothecin (51');
9-amino-12-(2-methoxycarbonyl-ethyl)camptothecin (52');
20 9-amino-12-(2-hydroxycarbonyl-ethyl)camptothecin (53');
9-amino-12-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (54');
9-amino-12-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
55');
25 9-amino-12-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
56');
9-amino-12-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (57');
9-amino-12-(3-oxo-butyl)camptothecin (58');
30 9-amino-12-(3-oxo-3-phenyl-propyl)camptothecin (59');
9-amino-12-(2-aminocarbonyl-ethyl)camptothecin (60');
10-amino-9-ethyl camptothecin (61');

- 10-amino-9-(2-methoxycarbonyl-ethyl)camptothecin (62');
10-amino-9-(2-hydroxycarbonyl-ethyl)camptothecin (63');
10-amino-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (64');
5 10-amino-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
(65');
10-amino-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
(66');
10-amino-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
10 camptothecin (67');
10-amino-9-(3-oxo-butyl)camptothecin (68');
10-amino-9-(3-oxo-3-phenyl-3-one-propyl)camptothecin (69');
10-amino-9-(2-aminocarbonyl-ethyl)camptothecin (70');
12-ethyl camptothecin (71');
15 12-(2-methoxycarbonyl-ethyl)camptothecin (72');
12-(2-hydroxycarbonyl-ethyl)camptothecin (73');
12-[(2R,S)-(2-acetylamino-2-methoxycarbonyl)-
ethyl]camptothecin (74');
12-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin (75');
20 12-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin (76');
12-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]camptothecin (77');
12-(3-oxo-butyl)camptothecin (78');
12-(3-oxo-3-phenyl-propyl)camptothecin (79');
12-(2-aminocarbonyl-ethyl)camptothecin (80');
25 10-hydroxy-9-ethyl camptothecin (81');
10-hydroxy-9-(2-methoxycarbonyl-ethyl)camptothecin (82');
10-hydroxy-9-(2-hydroxycarbonyl-ethyl)camptothecin (83');
10-hydroxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl]
camptothecin (84');
30 10-hydroxy-9-[(2-amino-2-methoxycarbonyl)-ethyl]camptothecin
(85');

- 10-hydroxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (86');
10-hydroxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin (87');
5 10-hydroxy-9-(3-oxo-butyl) camptothecin (88');
10-hydroxy-9-(3-oxo-3-phenyl-3-one-propyl) camptothecin (89');
10-hydroxy-9-(2-aminocarbonyl-ethyl) camptothecin (90');
10,11-methylenedioxy-9-ethyl camptothecin (91');
10,11-methylenedioxy-9-(2-methoxycarbonyl-ethyl) camptothecin
10 (92');
10,11-methylenedioxy-9-(2-hydroxycarbonyl-ethyl) camptothecin (93');
10,11-methylenedioxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl] camptothecin (94');
15 10,11-methylenedioxy-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (95');
10,11-methylenedioxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl] camptothecin (96');
10,11-methylenedioxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl] camptothecin (97');
20 10,11-methylenedioxy-9-(3-oxo-butyl) camptothecin (98');
10,11-methylenedioxy-9-(3-oxo-3-phenyl-propyl) camptothecin (99');
10,11-methylenedioxy-9-(2-aminocarbonyl-ethyl) camptothecin
25 (100');
10-methoxy-9-ethyl camptothecin (101');
10-methoxy-9-(2-methoxycarbonyl-ethyl) camptothecin (102');
10-methoxy-9-(2-hydroxycarbonyl-ethyl) camptothecin (103');
10-methoxy-9-[(2-acetylamino-2-methoxycarbonyl)-ethyl] camptothecin (104');
30 10-methoxy-9-[(2-amino-2-methoxycarbonyl)-ethyl] camptothecin (105');

10-methoxy-9-[(2-amino-2-hydroxycarbonyl)-ethyl]camptothecin
(106');

10-methoxy-9-[(2-acetylamino-2-hydroxycarbonyl)-ethyl]
camptothecin (107');

5 10-methoxy-9-(3-oxo-butyl)camptothecin (108');

10-methoxy-9-(3-oxo-3-phenyl-propyl)camptothecin (109');


10-methoxy-9-(2-aminocarbonyl-ethyl)camptothecin (110');

and, where a salifiable substituent is present on the molecule
framework, their pharmaceutically acceptable salts.

10

4. A process for preparing a compound of formula (I) as
defined in claim 1 or a pharmaceutically acceptable salt
thereof, said process comprising

1) reacting a compound of formula (II)



15


wherein

R₁₁ is a halogen atom, -OSO₂R₁₂ wherein wherein R₁₂ is C₁-C₅
alkyl unsubstituted or substituted at the terminal carbon atom
by one, two or three halogen atoms or an optionally
20 substituted phenyl ring;

R₄ is hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl or phenyl C₁-C₆
alkyl; and

X is hydrogen, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₁-C₆ alkoxy, C₃-
C₇ cycloalkoxy, C₁-C₆ alkanoyloxy, benzoyloxy, amino hydroxy,
25 nitro, halogen or it is a methylenedioxy group linked to the
positions 10 and 11 of the molecule, with a compound of
formula (III)


- 62 -



wherein

R_1 , R_2 and R_3 are as defined under (a) or (b) below:

- (a) R_1 and R_2 are each independently hydrogen; C_1 - C_4 alkyl; C_3 - C_7 cycloalkyl; phenyl C_1 - C_6 alkyl; an optionally substituted phenyl ring;
- NR_5R_6 wherein one of R_5 and R_6 is hydrogen, C_1 - C_6 alkyl or benzyl and the other is hydrogen C_1 - C_6 alkanoyl, an optionally substituted benzoyl, phenyl C_1 - C_6 alkanoyl, an optionally substituted C_1 - C_6 alkoxy carbonyl, an optionally substituted phenoxy carbonyl or phenyl C_1 - C_6 alkoxy carbonyl, or R_5 and R_6 , combined together with the nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring, represented by a group (G)



wherein W is $-C=O$, R_7 is hydrogen or C_1 - C_6 alkyl and n is an integer of 2 to 5;

$COOR_8$ wherein R_8 is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl or phenyl C_1 - C_6 alkyl; or

COR_9 wherein R_9 is C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, phenyl C_1 - C_6 alkyl, an optionally substituted phenyl ring, $NR_{10}R_{11}$ wherein R_{10} and R_{11} are each independently hydrogen or C_1 - C_6 alkyl; and

R_3 is hydrogen, C_1 - C_6 alkyl or an optionally substituted phenyl; or

(b) R_1 and R_3 , combined together, form a 5-8 membered, optionally substituted carbomonocyclic ring; and

R₂ is hydrogen, C₁-C₄ alkyl or C₃-C₇ cycloalkyl;
so obtaining a compound of formula (I) wherein the symbol
==== represents a double bond;
and, if desired,

- 5 2) optionally reducing a compound of formula (I) (as obtained
under step 1) into a corresponding compound of formula (I)
wherein the symbol ---- represents a single bond, and/or if
desired, salifying a compound of formula (I).

10 5. A pharmaceutical composition which comprises a compound
of formula (I) as claimed in claim 1 or a pharmaceutically
acceptable salt thereof as an active ingredient and a
pharmaceutically acceptable carrier and/or diluent.

15 6. A compound of formula (I) as claimed in claim 1 or a
pharmaceutically acceptable salt thereof for use as an
antitumor agent.

INTERNATIONAL SEARCH REPORT

Intern: al Application No
PCT/EP 96/02008

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D491/22 A61K31/435 //(C07D491/22,311:00,221:00,221:00,
209:00),(C07D491/22,317:00,311:00,221:00,221:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 325 247 (KABUSHIKI KAISHA YAKULT HONSHA) 26 July 1989 see page 8, line 51 - page 9, line 23; claims 1,15; example 16 ---	1,5
X	WO,A,91 04260 (RESEARCH TRIANGLE INSTITUTE) 4 April 1991 see claims 1,33; example 15 ---	1,5
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 1, 1991, WASHINGTON US, pages 98-107, XP002013003 W. D. KINGSBURY ET AL.: "Synthesis of water soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity" see compounds 19 and 35 in tables I and II --- -/--	1,5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

10 September 1996

Date of mailing of the international search report

13.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/02008

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 110, no. 15, 1989 Columbus, Ohio, US; abstract no. 128163n, W. K. ENG ET AL.: "Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin" page 30; XP002013004 see abstract and 12 Coll. Index, Chem. Subst., p. 78043, c.3 (101-103) and p. 78044, c.1 (71-73) & MOL. PHARMACOL, vol. 36, no. 4, 1988, pages 755-760, -----</p>	1,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/02008

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-325247	26-07-89	JP-A-	1186892	26-07-89
		JP-B-	6015547	02-03-94
		CA-A-	1332414	11-10-94
		DE-T-	68906552	16-12-93
		ES-T-	2056962	16-10-94
		US-A-	5061800	29-10-91

WO-A-9104260	04-04-91	AU-B-	640950	09-09-93
		US-A-	5180722	19-01-93



Jesse E
Esquivel/Complementary/IT/G
SK

11-Nov-2004 14:50

To Downs C Brown/IT/GSK@GSK
cc Joyce M Hartnett/CORP/GSK@GSK, Valerie L
Phillips/CORP/GSK@GSK
bcc
Subject KOP100000962698 - Joyce Hartnett Print Spooling Issues

Downs,

I recieved a phone call from a client named Valerie Phillips. Her and Joyce Hartnett are both continuing to experience the same spooling issues with a network printer that you worked on in late October. I am having the ticket reactivated in your name for further investigation.

You may contact Valerie Phillips at 3-8223 with updates.

Network Printer : - Very Slow printing Since server path convresion yesterday even when Q is empty. - PDF file

HP laserjet 550DN
\\rtpspprt002\rtpnmpn0096

Thanks for helping the clients out on this!

Jesse Esquivel
GSK Deskside Support - Level 3
Siemens Business Services Lead Technician
GlaxoSmithKline - RTP
Office: (919) 483-7162
Pager: (888) 791-9544